Department of Nuclear Medicine, Hôpital Tenon-AP-HP, Sorbonne Université, Paris, France.
Department of Urology, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France.
Sci Rep. 2020 Feb 7;10(1):2104. doi: 10.1038/s41598-020-58975-8.
We aimed to evaluate the impact of prostate-specific membrane antigen ligand labelled with gallium-68 (PSMA-11) PET/CT in restaging patients with castration-resistant nonmetastatic prostate cancer (PCa). Thirty patients were included. At least one malignant focus was found in 27/30 patients (90%). The PSMA-11 PET/CT positivity rate in patients whose prostate-specific antigen serum level (PSA) was greater than 2 ng/ml was 100% (20/20), significantly superior to that of patients whose PSA was less than 2 ng/ml (7/10 = 70%). Six patients (20%) were categorized as oligometastatic (≤3 metastatic foci). Based on the 17 patients for whom a standard of truth was feasible, the overall sensitivity and specificity of PSMA-11 PET/CT in detecting residual disease in castration-resistant PCa patients were 87% and 100% respectively. PSMA-11 PET/CT impacted patients' disease management in 70% of cases, 60% of case when PSA was less than 2 ng/ml. This management was considered as adequate in 91% of patients. PSMA-11 PET/CT appeared to be effective in restaging patients with castration-resistant nonmetastatic PCa. PSMA-11 PET/CT should be considered as a replacement for bone scans under these conditions.
我们旨在评估镓-68 标记的前列腺特异性膜抗原配体（PSMA-11）PET/CT 在去势抵抗性非转移性前列腺癌（PCa）患者中的再分期作用。共纳入 30 例患者。在 30 例患者中至少有 1 个恶性病灶，27/30 例（90%）发现了恶性病灶。血清前列腺特异性抗原（PSA）水平大于 2ng/ml 的患者中 PSMA-11 PET/CT 阳性率为 100%（20/20），显著高于 PSA 小于 2ng/ml 的患者（7/10=70%）。6 例患者（20%）为寡转移（≤3 个转移灶）。对于有标准参考的 17 例患者，PSMA-11 PET/CT 检测去势抵抗性 PCa 患者残留疾病的总敏感性和特异性分别为 87%和 100%。PSMA-11 PET/CT 影响了 70%患者的疾病管理，在 PSA 小于 2ng/ml 的患者中影响了 60%患者的疾病管理。91%的患者认为这种管理是充分的。PSMA-11 PET/CT 似乎在去势抵抗性非转移性 PCa 患者的再分期中是有效的。在这些情况下，PSMA-11 PET/CT 应该被考虑替代骨扫描。
